CARLSBAD, Calif.–(BUSINESS WIRE)–Carlsmed, a commercial-stage medical technology company and pioneer of the personalized spine surgery market, today announced the successful launch of its state-of-the-art digital production line. This innovative technology will enable the company to deliver its aprevo® personalized spinal fusion implants to hospitals in less than ten days.
“This advancement is more than just a technical achievement,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “The reduced lead time makes aprevo® available for surgeries with shorter scheduling windows, increasing addressable procedures and furthering our commitment to making personalized surgery accessible to every patient who needs it.”
Carlsmed’s current portfolio of patient-specific devices is indicated for use in lumbar spine fusion surgery. The company is developing patient-specific implants for cervical spine fusion surgery and received FDA Breakthrough Device designation for cervical fusions earlier this year. The launch of aprevo® for cervical fusions is expected by the end of 2025.
“The aprevo® implants were crucial for my recovery,” said Renee Schreiner, a patient who received the aprevo® procedure. “When my surgeon told me that personalized spine surgery was available to me, I immediately felt more comfortable choosing to have surgery. Knowing that my implant was designed just for me made all the difference.”
Carlsmed is dedicated to innovation and excellence in personalized healthcare, ensuring that it meets the unique needs of every individual it serves. Clinical publications show significant improvements in patient outcomes for aprevo® personalized procedures compared to traditional spine fusion surgery.
About Carlsmed
Carlsmed is a commercial stage medical technology company and leader of the personalized spine surgery market. aprevo® is the only commercially available custom made anatomically designed interbody for spine fusion surgery.
Contacts
For media and investor inquiries, please contact Jodi Allen at [email protected].
Leave a Reply